Mobius Therapeutics Continues Production and Distribution of Mitosol

Mobius Therapeutics, the maker of Mitosol (mitomycin for solution) 0.2 mg/vial kit for ophthalmic use, has maintained production and inventory of Mitosol, recognizing the nonelective nature of the patient population affected by its intended use.  Mitosol is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication.

“During this global crisis, surgical volume has experienced a dramatic decline. However, the ultimate need for these surgeries has not dissipated,” Ed Timm, CEO of Mobius, said in a company news release. “As Mitosol plays a unique and critical role in improving the efficacy of these surgeries and the preservation of patient vision, we stand resolute in our commitment to patient care.”

With room temperature storage and shelf life of up to 24 months, Mitosol offers unique flexibility to providers, as its “shelf-ready” status permits on-demand utility.

“The near-term future of patient care remains uncertain,” Mr. Timm said. “Irrespective of this volatility, Mobius’ commitment to patients and providers remains undeterred. We remain here for you now, as well as into the future.”